Glaspimod (SK&F 107647) is a synthetic hematoregulatory peptide that shares biological and/or modulatory activities with natural hematopoietic cytokines. The peptide has been tested in vitro and in vivo for hematopoietic effects (involvement in production of cellular blood components). In vitro, glaspimod has no direct colony-stimulating activity (CSA), In vivo, injection of the compound results in an increase in serum CSA (maximal at 6 hours after injection). With repeated administration, significant increases in absolute numbers of granulocyte-macrophage (CFU-GM), erythroid (BFU-E), and multipotential (CFU-GEMM) progenitor cells can be measured. Pharmacokinetic effects of glasmipod have been studied in patients with adenocarcinoma and were not amenable to standard therapy.